Photo of Daniel Shortt

Daniel is a Seattle-based corporate and regulatory attorney who works extensively with entrepreneurs in the cannabis industry. He advises clients on matters related to both hemp and marijuana and frequently speaks on legal issues relating to cannabis across the country and abroad. Daniel is quoted as an authority on cannabis law in dozens of publications, including Marijuana Moment, Hemp Industry Daily, the Washington Post, and Bloomberg, to name a few.

On December 9, 2022, the New York Office of Cannabis Management (OCM) released Cannabis Delivery Guidance allowing retail dispensaries, including Adult-Use Retail Dispensary (CAURD) licensees, the ability to deliver cannabis to customers directly in hopes to “jumpstart” cannabis sales before the end of the year. We previously wrote about the

Continue Reading New York to Allow Adult-Use Cannabis Delivery

The Washington State Liquor and Cannabis Board (LCB) recently adopted an Interpretive Statement on the use of Additives in Authorized Cannabis Products. The Interpretive Statement is described by the LCB as follows:

This interpretive statement describes the use of CBD products and other additives and whether other cannabinoids, such

Continue Reading LCB Interpretive Statement Bans Hemp-Derivatives Besides CBD

On Friday, December 2, 2022, the White House announced that President Biden signed House Resolution 8454 into law:

H.R. 8454, the “Medical Marijuana and Cannabidiol Research Expansion Act,” establishes a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development.


Continue Reading The New Marijuana Research Bill Is Another Sign That Federal Prohibition is Ending

On November 10, 2022, a federal judge temporarily stopped the Office of Cannabis Management (OCM) from issuing conditional adult-use retail dispensary (CAURD) licenses in certain parts of New York. The reason: the CAURD application contained New York residency requirements that may violate the U.S. Constitution (specifically, a court-created doctrine called

Continue Reading Judge Puts New York Dispensary Licenses on Pause on Dormant Commerce Clause Grounds

The Cannabis Control Board (CCB) and Office of Cannabis Regulations (OCM) recently issued “Guidance for Adult-Use Retail Dispensaries.” The twenty-seven-page document provides insight into what the Conditional Adult-Use Retail Dispensaries (CAURD) regulations will look like and will shape the non-conditional retail dispensaries license regulations down the road. We will cover

Continue Reading New York Takes a Hard Stand Against Vertical Integration

According to a recent article from Upstate New York, the state of New York is confronting an issue commonly faced in the state-legal cannabis industry, a lack of banking options. The New York regulators need an account for the Seeding Opportunity Initiative fund of $200M, which will go to

Continue Reading What Will New York Do if Dispensaries Do Not Open in Time?

It appears that President Joe Biden is prepared to take real, legitimate steps to completely change policy on cannabis at a federal level.

On October 6, 2022, the official Twitter account of the office of the President presented a plan through a series of Tweets.

The plan is detailed as

Continue Reading Major Cannabis Announcement from President Biden

The United States Court of International Trade recently issued an opinion on whether a company in Washington state could import drug paraphernalia, specifically cannabis-trimming equipment. That case, Eteros Technologies USA vs. United States, concerns “the interplay between the federal and state systems, specifically the Washington State system, governing

Continue Reading Cannabis Paraphernalia: Custom and Border Protection Loses Case

After ten years of cannabis legalization, Washington is poised to establish a social equity cannabis program. Social equity applicants who qualify have the opportunity to obtain cannabis retail licenses from the Washington State Liquor and Cannabis Board (WSLCB). This post focuses on the WSLCB’s draft rules, which may undergo

Continue Reading Washington Cannabis Social Equity FAQs

The United States Food and Drug Administration (FDA) has consistently taken the position that cannabidiol derived from hemp (CBD) cannot be marketed or sold as a dietary supplement or food. The FDA’s position is based on the fact that CBD has been approved for use in a pharmaceutical drug and

Continue Reading The FDA is Quietly Targeting CBD in 2022